CO2024006269A2 - Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos - Google Patents

Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos

Info

Publication number
CO2024006269A2
CO2024006269A2 CONC2024/0006269A CO2024006269A CO2024006269A2 CO 2024006269 A2 CO2024006269 A2 CO 2024006269A2 CO 2024006269 A CO2024006269 A CO 2024006269A CO 2024006269 A2 CO2024006269 A2 CO 2024006269A2
Authority
CO
Colombia
Prior art keywords
usp1
ubiquitin
specific protease
small molecule
molecule inhibitors
Prior art date
Application number
CONC2024/0006269A
Other languages
English (en)
Inventor
Jianping Wu
Luoheng Qin
Jinxin Liu
Original Assignee
Insilico Medicine Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insilico Medicine Ip Ltd filed Critical Insilico Medicine Ip Ltd
Publication of CO2024006269A2 publication Critical patent/CO2024006269A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La descripción proporciona compuestos inhibidores de moléculas pequeñas de proteasa 1 específica de ubiquitina (USP1) y composiciones que comprenden los mismos. La descripción proporciona además métodos para dirigirse a proteasa 1 específica de ubiquitina (USP1) y métodos para tratar enfermedades o trastornos relacionados con USP1, tal como cáncer.
CONC2024/0006269A 2021-11-12 2024-05-17 Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos CO2024006269A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021130290 2021-11-12
CN2022123827 2022-10-08
PCT/CN2022/131293 WO2023083286A1 (en) 2021-11-12 2022-11-11 Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof

Publications (1)

Publication Number Publication Date
CO2024006269A2 true CO2024006269A2 (es) 2024-05-30

Family

ID=86335131

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0006269A CO2024006269A2 (es) 2021-11-12 2024-05-17 Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos

Country Status (10)

Country Link
US (2) US11739077B2 (es)
EP (1) EP4430050A1 (es)
KR (1) KR20240117556A (es)
AR (1) AR127646A1 (es)
AU (1) AU2022386486A1 (es)
CA (1) CA3235765A1 (es)
CO (1) CO2024006269A2 (es)
IL (1) IL312642A (es)
TW (1) TW202334142A (es)
WO (1) WO2023083286A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086790A1 (en) * 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
SI1140941T1 (en) * 1998-12-23 2005-04-30 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
EP1364950A4 (en) 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
WO2010060854A1 (en) 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP2615916B1 (en) * 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
KR20140077912A (ko) 2011-09-16 2014-06-24 사노피 치환된 4,5,6,7-테트라하이드로-1H-피라졸로[4,3-c]피리딘, 약물로서의 그 용도, 및 그를 포함한 약제학적 제제
CA2896731A1 (en) 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CN107531690B (zh) 2014-11-27 2020-11-06 基因泰克公司 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
CA3005353A1 (en) * 2015-11-20 2017-05-26 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
BR112018012914B1 (pt) 2015-12-22 2023-04-18 SHY Therapeutics LLC Composto, uso de um composto e composição farmacêutica
CN109476663B (zh) 2016-05-24 2021-11-09 基因泰克公司 用于治疗癌症的吡唑并吡啶衍生物
SG11201911929XA (en) 2017-06-21 2020-01-30 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3703669A4 (en) 2017-11-01 2021-11-10 Dana-Farber Cancer Institute, Inc. CANCER TREATMENT METHODS
WO2020132269A1 (en) * 2018-12-20 2020-06-25 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
EP3902802A4 (en) 2018-12-28 2022-09-07 Forma Therapeutics, Inc. COMPOSITIONS FOR INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1
IL295149A (en) * 2020-02-14 2022-09-01 Ksq Therapeutics Inc Therapeutic combinations containing ubiquitin-specific processing protease 1 (usp1) inhibitors and poly(adp-ribose) polymerase (parp) inhibitors
US20230219965A1 (en) 2020-06-02 2023-07-13 KSQ Therapeutics, Inc. Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
CA3196564A1 (en) 2020-10-30 2022-05-05 Hanlan Liu Solid state forms of substituted pyrazolopyrimidines and uses thereof
MX2023009086A (es) 2021-02-12 2023-08-08 Relay Therapeutics Inc Inhibidores de cinasas dependientes de ciclinas (cdk) y metodos de uso de estos.
US20240182481A1 (en) 2021-02-15 2024-06-06 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
WO2022197892A1 (en) 2021-03-17 2022-09-22 Tango Therapeutics, Inc. Purine derivatives as anticancer agents
WO2022199652A1 (en) 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
EP4319758A1 (en) 2021-04-07 2024-02-14 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 1 (usp1)
BR112023020442A2 (pt) 2021-04-09 2023-11-21 Simcere Zaiming Pharmaceutical Co Ltd Inibidor da protease 1 específica de ubiquitina (usp1)
PE20241350A1 (es) 2021-11-12 2024-07-03 Insilico Medicine Ip Ltd Inhibidores de moleculas pequenas de la proteasa especifica de ubiquitina 1 (usp1) y sus usos
AU2022384416A1 (en) 2021-11-12 2024-05-16 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof

Also Published As

Publication number Publication date
US20240190839A1 (en) 2024-06-13
KR20240117556A (ko) 2024-08-01
CA3235765A1 (en) 2023-05-19
EP4430050A1 (en) 2024-09-18
AR127646A1 (es) 2024-02-14
US20230183210A1 (en) 2023-06-15
IL312642A (en) 2024-07-01
US11739077B2 (en) 2023-08-29
WO2023083286A1 (en) 2023-05-19
TW202334142A (zh) 2023-09-01
AU2022386486A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
CO2024006279A2 (es) Inhibidores de molécula pequeña de proteasa específica de ubiquitina 1 (usp1) y usos de los mismos
CO2024006269A2 (es) Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
CO2024006278A2 (es) Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos
PA8541601A1 (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7.
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
UY26285A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
CR9580A (es) Inhibidores de la actividad akt
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
PA8675701A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
CL2004000848A1 (es) Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
CR10766A (es) Inhibidores de metaloproteasa derivados de heterociclicos
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
CO2022016504A2 (es) Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos
CO2022016514A2 (es) Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos
CL2023001339A1 (es) Un inhibidor de magl.